References
- World Health Organization. Global Cancer Observatory: cancer Today; 2024 [cited 2024 January]. Available from: https://gco.iarc.fr/
- World Health Organization. Global Breast Cancer Initiative Implementation Framework: assessing, strengthening and scaling-up of services for the early detection and management of breast cancer. Geneva: World Health Organization; 2023.
- Federal Statistics Office. Swiss Cancer Report. Neuchâtel: Federal Statistics Office; 2021.
- Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938–1948. doi: 10.1056/NEJMra1001389.
- Huang M, Haiderali A, Fox GE, et al. Economic and humanistic burden of triple-negative breast cancer: a systematic literature review. Pharmacoeconomics. 2022;40(5):519–558. doi: 10.1007/s40273-021-01121-7.
- McGuire A, Brown JA, Malone C, et al. Effects of age on the detection and management of breast cancer. Cancers (Basel). 2015;7(2):908–929. doi: 10.3390/cancers7020815.
- Ignatov A, Eggemann H, Burger E, et al. Patterns of breast cancer relapse in accordance to biological subtype. J Cancer Res Clin Oncol. 2018;144(7):1347–1355. doi: 10.1007/s00432-018-2644-2.
- Jamdade VS, Sethi N, Mundhe NA, et al. Therapeutic targets of triple‐negative breast cancer: a review. Br J Pharmacol. 2015;172(17):4228–4237. doi: 10.1111/bph.13211.
- Rezaei S, Babaei M. A systematic literature review on direct and indirect costs of triple-negative breast cancer. Cost Eff Resour Alloc. 2023;21(1):92. doi: 10.1186/s12962-023-00503-2.
- Sieluk J, Haiderali A, Huang M, et al. PCN240 healthcare resource utilization associated with disease recurrence among surgically-treated patients with triple-negative breast cancer. Value Health. 2021;24:S65. doi: 10.1016/j.jval.2021.04.330.
- Leuteritz K, Friedrich M, Sender A, et al. Return to work and employment situation of young adult cancer survivors: results from the Adolescent and Young Adult-Leipzig Study. J Adolesc Young Adult Oncol. 2021;10(2):226–233. doi: 10.1089/jayao.2020.0055.
- Heuser C, Halbach S, Kowalski C, et al. Sociodemographic and disease-related determinants of return to work among women with breast cancer: a German longitudinal cohort study. BMC Health Serv Res. 2018;18(1):1000. Dec 29 doi: 10.1186/s12913-018-3768-4.
- Rolland AL, Porro B, Kab S, et al. Impact of breast cancer care pathways and related symptoms on the return-to-work process: results from a population-based French cohort study (CONSTANCES). Breast Cancer Res. 2023;25(1):30. doi: 10.1186/s13058-023-01623-6.
- Varnier R, Moskal A, Dima AL, et al. 1620P Return to work trajectories after early breast cancer diagnosis: a population-based cohort study in the French National Healthcare Insurance database. Anna Oncol. 2022;33:S1282. doi: 10.1016/j.annonc.2022.07.1923.
- Lundh MH, Lampic C, Nordin K, et al. Sickness absence and disability pension following breast cancer - a population-based matched cohort study. Breast. 2014;23(6):844–851. Dec doi: 10.1016/j.breast.2014.09.007.
- Sieluk J, Song Y, Freimark J, et al. The economic burden of recurrence in triple-negative breast cancer among working age patients in the United States. Adv Ther. 2022;39(2):943–958. Feb doi: 10.1007/s12325-021-01913-5.
- Maunsell E, Drolet M, Brisson J, et al. Work situation after breast cancer: results from a population-based study. J Natl Cancer Inst. 2004;96(24):1813–1822. doi: 10.1093/jnci/djh335.
- Drolet M, Maunsell E, Mondor M, et al. Work absence after breast cancer diagnosis: a population-based study. CMAJ. 2005;173(7):765–771. doi: 10.1503/cmaj.050178.
- Humphries B, Lauzier S, Drolet M, et al. Wage losses among spouses of women with nonmetastatic breast cancer. Cancer. 2020;126(5):1124–1134. doi: 10.1002/cncr.32638.
- Syse A, Tretli S, Kravdal O. The impact of cancer on spouses’ labor earnings: a population-based study. Cancer. 2009;115(18 Suppl):4350–4361. doi: 10.1002/cncr.24582.
- Altice CK, Banegas MP, Tucker-Seeley RD, et al. Financial hardships experienced by cancer survivors: a systematic review. J Natl Cancer Inst. 2017;109(2):djw205. doi: 10.1093/jnci/djw205.
- Connolly MP, Kotsopoulos N, Postma MJ, et al. The fiscal consequences attributed to changes in morbidity and mortality linked to investments in health care: a government perspective analytic framework. Value Health. 2017;20(2):273–277. doi: 10.1016/j.jval.2016.11.018.
- Food and Drug Administration. FDA approves pembrolizumab for high-risk early-stage triple-negative breast cancer. 2021 [cited 2024 February]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-high-risk-early-stage-triple-negative-breast-cancer.
- European Medicines Agency. Summary of Product Characteristics - KEYTRUDA 25mg/mL concentrate for solution for infusion. 2020. Available from: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf.
- Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386(6):556–567. doi: 10.1056/NEJMoa2112651.
- Favre-Bulle A, Huang M, Haiderali A, et al. Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab in patients with high-risk, early-stage, triple-negative breast cancer in Switzerland. PharmacoEconomics-Open. 2023;8:1–11.
- Connolly MP. The fiscal impact of investments in health care. The future of health economics. 1st ed. London: Routledge; 2016.
- Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810–821. doi: 10.1056/NEJMoa1910549.
- Gidwani R, Russell LB. Estimating transition probabilities from published evidence: a tutorial for decision modelers. Pharmacoeconomics. 2020;38(11):1153–1164. doi: 10.1007/s40273-020-00937-z.
- Noeres D, Park-Simon TW, Grabow J, et al. Return to work after treatment for primary breast cancer over a 6-year period: results from a prospective study comparing patients with the general population. Support Care Cancer. 2013;21(7):1901–1909. doi: 10.1007/s00520-013-1739-1.
- Dumas A, Vaz Luis I, Bovagnet T, et al. Impact of breast cancer treatment on employment: results of a Multicenter Prospective Cohort Study (CANTO). J Clin Oncol. 2020;38(7):734–743. Mar 1 doi: 10.1200/JCO.19.01726.
- Ribi K, Pagan E, Sala I, et al. Employment trajectories of young women with breast cancer: an ongoing prospective cohort study in Italy and Switzerland. J Cancer Surviv. 2023;17(6):1847–1858. Dec doi: 10.1007/s11764-022-01222-y.
- OECD. LFS by sex and age - indicators. 2023 [cited 2023 November]. Available from: https://stats.oecd.org/Index.aspx?DataSetCode=lfs_sexage_i_r.
- Federal Statistics Office. Gross monthly wage (median and quartile range) by age, professional position and gender - Private and public sectors combined [T9_b]. 2023 [cited 2023 November]. https://www.bfs.admin.ch/bfs/de/home/statistiken/kataloge-datenbanken/tabellen.assetdetail.30385232.html.
- Federal Statistics Office. CPI (december 2020 = 100), detailed results since 1982, structure of basket 2020, including additional classifications. [LIK20B20]. [cited 2023 November]. Available from: https://www.bfs.admin.ch/bfs/en/home/statistics/prices/consumer-price-index.assetdetail.27085446.html.
- Federal Statistics Office. Invalides bénéficiaires de rente en Suisse en décembre selon le sexe, la classe d‘âge et la cause d‘invalidité. [cited 2023 November]. Available from: https://www.bfs.admin.ch/asset/fr/px-x-1305010000_111.
- Federal Statistics Office. Absences. [cited 2023 November]. Available from: https://www.bfs.admin.ch/bfs/en/home/statistics/work-income/employment-working-hours/working-hours/absences.html.
- OECD. Taxing wages - Switzerland. Paris: OECD Publishing; 2023.
- Federal Tax Administration FTA. Development of the Swiss VAT rates. [cited 2023 November]. Available from: https://www.estv.admin.ch/estv/en/home/value-added-tax/vat-rates-switzerland/development-of-the-swiss-vat-rates.html.
- Ferrier C, Thebaut C, Levy P, et al. Absenteeism and indirect costs during the year following the diagnosis of an operable breast cancer: a prospective multicentric cohort study. J Gynecol Obstet Hum Reprod. 2021;50(6):101871. doi: 10.1016/j.jogoh.2020.101871.
- Cong Z, Tran O, Nelson J, et al. Productivity loss and indirect costs for patients newly diagnosed with early-versus late-stage cancer in the USA: a large-scale observational research study. Appl Health Econ Health Policy. 2022;20(6):845–856. doi: 10.1007/s40258-022-00753-w.
- Wan Y, Gao X, Mehta S, et al. Indirect costs associated with metastatic breast cancer. J Med Econ. 2013;16(10):1169–1178. doi: 10.3111/13696998.2013.826228.
- Reeves A, Basu S, McKee M, et al. Does investment in the health sector promote or inhibit economic growth? Global Health. 2013;9(1):43. doi: 10.1186/1744-8603-9-43.
- Stuckler D, Reeves A, Mckee M. Social and economic multipliers: what they are and why they are important for health policy in Europe. Scand J Public Health. 2017;45(18_suppl):17–21. doi: 10.1177/1403494817707124.
- Federal Office of Public Health (FOPH). Health2030 – the Federal Council’s health policy strategy for the period 2020–2030. Bern: Federal Office of Public Health (FOPH); 2019.